11/21
10:07 am
ibrx
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment [Yahoo! Finance]
Medium
Report
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment [Yahoo! Finance]
11/21
10:00 am
ibrx
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Medium
Report
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
11/19
11:53 am
ibrx
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet [Yahoo! Finance]
11/19
09:00 am
ibrx
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
Medium
Report
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
11/19
08:20 am
ibrx
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months [Yahoo! Finance]
Medium
Report
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months [Yahoo! Finance]
11/19
08:00 am
ibrx
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
Medium
Report
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
11/14
08:08 am
ibrx
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon [Globe and Mail, The (Toronto, Canada)]
Low
Report
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon [Globe and Mail, The (Toronto, Canada)]
11/12
07:15 am
ibrx
ImmunityBio Reports Third-Quarter 2024 Financial Results
High
Report
ImmunityBio Reports Third-Quarter 2024 Financial Results
10/30
09:00 pm
ibrx
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/28
05:36 am
ibrx
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Medium
Report
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? [Yahoo! Finance]
10/25
12:46 pm
ibrx
ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful [Seeking Alpha]
Medium
Report
ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful [Seeking Alpha]
10/25
05:37 am
ibrx
ImmunityBio commences CD19 t-haNK cell therapy trial for NHL [Yahoo! Finance]
Medium
Report
ImmunityBio commences CD19 t-haNK cell therapy trial for NHL [Yahoo! Finance]
10/24
09:00 am
ibrx
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
High
Report
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
10/24
07:26 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
High
Report
ImmunityBio, Inc. (NASDAQ: IBRX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
10/23
03:38 pm
ibrx
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio [Yahoo! Finance]
Low
Report
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio [Yahoo! Finance]
10/21
09:00 am
ibrx
ImmunityBio to Participate in the Jefferies London Healthcare Conference
Low
Report
ImmunityBio to Participate in the Jefferies London Healthcare Conference
10/11
04:25 pm
ibrx
IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX
Low
Report
IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX
10/7
11:38 am
ibrx
ImmunityBio: Moving The Needle [Seeking Alpha]
Low
Report
ImmunityBio: Moving The Needle [Seeking Alpha]
9/12
04:12 pm
ibrx
Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider [Yahoo! Finance]
Low
Report
Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider [Yahoo! Finance]
9/9
08:30 am
ibrx
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
Medium
Report
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
8/29
12:49 am
ibrx
A Billionaire Saved A Nonprofit. Then Things Got Ugly [Forbes]
Medium
Report
A Billionaire Saved A Nonprofit. Then Things Got Ugly [Forbes]